Mobile website
Archive > Volume 20 Issue 4 > 2013,20(4):461-467. DOI:10.3872/j.issn.1007-385X.2013.04.014 Prev Next
Clinical Research
A Meta-analysis of adoptive immunotherapy combined with chemo/radio therapy in the treatment of non-small cell lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To systematically assess the therapeutic effectiveness of adoptive immunotherapy combined with chemo/radio therapy compared with chemo/radio therapy alone in non-small cell lung cancer (NSCLC) patients. Methods: A systematic search of Pubmed, Medline, EMBASE, Cochrane Library, CNKI and VIP database from January 1995 to September 2012 was performed to identify the eligible randomized controlled trials (RCTs) and non-randomized concurrent controlled trails (NRCCTs). The improper documents were excluded. The soft-ware Revman5.0 was used for data synthesis. Results: A total of 10 studies involving 1 326 patients were identified. The result of Meta-analyses showed that adoptive immunotherapy combined with radio/chemo therapy improved the 2-year progression-free survival (PFS) (OR=2.20, 95%CI：1.44-3.36, P=0.0003) and 2-year overall survival (OR=2.69, 95%CI：1.92-3.78, P<000001). Both early-stage and advanced NSCLC patients benefited from adoptive immunotherapy (OR=3.24\[1.65-6.35\]; OR=2.86\[1.37-5.98\]). The adverse events were self limiting, including fever, chill, nausea, and fatigue. No severe toxicity was observed. Conclusion: Adoptive immunotherapy combined with chemo/radio therapy can decrease the risk of recurrence and improve the overall survival of NSCLC patients; early-stage patients receiving adoptive immunotherapy may benefit more.
Keywords:
Project Supported:
Project supported by the National Key Basic Research Development Program (973 Program) of China (No. 2012CB9333004), the National High Technology Research and Development Program (863 Program) of China (No. SS2012AA020403), and the Special Foundation for Clinical Trials of Cancer Hospital (No. 11L01）
Clc Number:
